Investors

As a late clinical-stage biopharmaceutical company focused on oncology, our business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Our lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, and has reported positive results from a pre-planned pharmacoeconomic study. These outstanding results support the goal of Motixafortide becoming the standard of care mobilization agent in autologous bone-marrow transplantation, and in this regard we are currently preparing an NDA submission.read more

 

I.R. Contacts

If you would like further information or have questions or comments, please contact:

Tim McCarthy
LifeSci Advisors, LLC
+1-212-915-2564
tim@lifesciadvisors.com

Media inquiries:

Moran Meir
LifeSci Advisors, LLC
+972-54-476-4945
moran@lifesciadvisors.com